WO2007127936A3 - Methods and compositions for antibody therapy - Google Patents

Methods and compositions for antibody therapy Download PDF

Info

Publication number
WO2007127936A3
WO2007127936A3 PCT/US2007/067663 US2007067663W WO2007127936A3 WO 2007127936 A3 WO2007127936 A3 WO 2007127936A3 US 2007067663 W US2007067663 W US 2007067663W WO 2007127936 A3 WO2007127936 A3 WO 2007127936A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphism
methods
fcϝriiia
fcϝriia
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/067663
Other languages
French (fr)
Other versions
WO2007127936A2 (en
Inventor
Vijay Ramakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PIKAMAB Inc
Original Assignee
PIKAMAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PIKAMAB Inc filed Critical PIKAMAB Inc
Priority to EP07761485A priority Critical patent/EP2027291A2/en
Priority to CA002650730A priority patent/CA2650730A1/en
Priority to US12/298,661 priority patent/US8592149B2/en
Priority to AU2007244683A priority patent/AU2007244683A1/en
Publication of WO2007127936A2 publication Critical patent/WO2007127936A2/en
Publication of WO2007127936A3 publication Critical patent/WO2007127936A3/en
Anticipated expiration legal-status Critical
Priority to US14/065,391 priority patent/US20140170670A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcϜRIIA polymorphism, or a FcϜRIIIA polymorphism, or both an FcϜRIIA polymorphism and a FcϜRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcϜRIIA polymorphism, or FcϜRIIIA polymorphism, or both the FcϜRIIA polymorphism and the FcϜRIIIA polymorphism.
PCT/US2007/067663 2006-04-27 2007-04-27 Methods and compositions for antibody therapy Ceased WO2007127936A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07761485A EP2027291A2 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy
CA002650730A CA2650730A1 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy
US12/298,661 US8592149B2 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy
AU2007244683A AU2007244683A1 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy
US14/065,391 US20140170670A1 (en) 2006-04-27 2013-10-28 Methods and Compositions for Antibody Therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79595706P 2006-04-27 2006-04-27
US60/795,957 2006-04-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/298,661 A-371-Of-International US8592149B2 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy
US14/065,391 Continuation US20140170670A1 (en) 2006-04-27 2013-10-28 Methods and Compositions for Antibody Therapy

Publications (2)

Publication Number Publication Date
WO2007127936A2 WO2007127936A2 (en) 2007-11-08
WO2007127936A3 true WO2007127936A3 (en) 2008-05-15

Family

ID=38616540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067663 Ceased WO2007127936A2 (en) 2006-04-27 2007-04-27 Methods and compositions for antibody therapy

Country Status (5)

Country Link
US (2) US8592149B2 (en)
EP (2) EP2027291A2 (en)
AU (1) AU2007244683A1 (en)
CA (1) CA2650730A1 (en)
WO (1) WO2007127936A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027291A2 (en) * 2006-04-27 2009-02-25 Pikamab, Inc. Methods and compositions for antibody therapy
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc Predicting responsiveness to antibody maintenance therapy
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US12024568B2 (en) * 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
CA2983796A1 (en) * 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
EP3601346A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN107602702A (en) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 Antibody that is a kind of while targetting people p185 and VEGF and its application
EP3693465A1 (en) 2019-02-05 2020-08-12 Pharmaq AS Novel fish coronavirus
TWI884296B (en) 2020-08-11 2025-05-21 美商碩騰服務公司 Anti-coronavirus vaccines
IL300484A (en) * 2020-08-19 2023-04-01 Astellas Pharma Inc Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
CN114315985A (en) 2020-09-29 2022-04-12 硕腾服务有限责任公司 Attenuated porcine epidemic diarrhea virus
TW202325338A (en) 2021-08-06 2023-07-01 美商碩騰服務有限責任公司 Clostridium chauvoei vaccine and method of making
US20240390476A1 (en) 2021-08-31 2024-11-28 Zoetis Services Llc Attenuated alphavirus
JP2024542159A (en) * 2021-11-04 2024-11-13 アーティバ バイオセラピューティクス インコーポレイテッド Treating Cancer with NK Cells and Multispecific Engagers
KR20240102971A (en) 2021-11-16 2024-07-03 제넨테크, 인크. Method and composition for treating systemic lupus erythematosus (SLE) using mosunetuzumab
EP4453008A1 (en) 2021-12-20 2024-10-30 Zoetis Services LLC Compositions and methods for prevention of piscine myocarditis
AU2022419971A1 (en) 2021-12-20 2024-07-04 Zoetis Services Llc Use of interferon as an adjuvant in vaccines
EP4630048A1 (en) 2022-12-06 2025-10-15 Zoetis Services LLC Methods and compositions for vaccinating piglets against prrs-1 virus
DK202370610A1 (en) 2022-12-13 2024-07-12 Zoetis Services Llc Methods of vaccine administration to salmonids
WO2025090476A1 (en) 2023-10-24 2025-05-01 Zoetis Services Llc Canine oral vaccines and methods of administration
WO2025264964A1 (en) 2024-06-20 2025-12-26 Zoetis Services Llc Vaccines against tenacibaculum finnmarkense

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062929A2 (en) * 2003-12-22 2005-07-14 Chiron Coporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
US20060008825A1 (en) * 2004-06-18 2006-01-12 Ronald Levy Methods and compositions for determining responsiveness to antibody therapy
WO2007064957A1 (en) * 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4347935A (en) 1979-05-16 1982-09-07 The United States Of America As Represented By The United States Department Of Energy Method and apparatus for electrostatically sorting biological cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (en) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
ATE105585T1 (en) 1987-12-21 1994-05-15 Univ Toledo TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
FI85768C (en) 1990-07-04 1992-05-25 Valtion Teknillinen Method for performing surface plasmon resonance measurement and in method t useful sensor
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE69123241T2 (en) 1990-12-14 1997-04-17 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTING RECEPTOR-RELATED SIGNAL PATHS
EP0517930B1 (en) 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5464581A (en) 1993-08-02 1995-11-07 The Regents Of The University Of California Flow cytometer
US5483469A (en) 1993-08-02 1996-01-09 The Regents Of The University Of California Multiple sort flow cytometer
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
JPH10503371A (en) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー New compound
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5602039A (en) 1994-10-14 1997-02-11 The University Of Washington Flow cytometer jet monitor system
US5643796A (en) 1994-10-14 1997-07-01 University Of Washington System for sensing droplet formation time delay in a flow cytometer
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP2002515738A (en) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド Nucleic acid analysis
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US6211477B1 (en) 1998-02-26 2001-04-03 Becton Dickinson And Company Electrostatic deceleration system for flow cytometer
EP1080365A1 (en) 1998-05-20 2001-03-07 Graffinity Pharmaceuticals Aktiengesellschaft Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form
US6259286B1 (en) 1999-10-15 2001-07-10 Triscend Corporation Method and apparatus for a power-on-reset system
AU2002346999B2 (en) * 2001-10-19 2007-11-08 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
EP2027291A2 (en) * 2006-04-27 2009-02-25 Pikamab, Inc. Methods and compositions for antibody therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062929A2 (en) * 2003-12-22 2005-07-14 Chiron Coporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
US20060008825A1 (en) * 2004-06-18 2006-01-12 Ronald Levy Methods and compositions for determining responsiveness to antibody therapy
WO2007064957A1 (en) * 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLYNES RAPHAEL: "Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, vol. 20, no. 3, June 2006 (2006-06-01), pages 585 - 612, XP008083800, ISSN: 0889-8588 *
HATJIHARISSI E ET AL: "Genetic linkage of Fc[gamma]RIIa and Fc[gamma]RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy", CLINICAL LYMPHOMA AND MYELOMA 2007 UNITED STATES, vol. 7, no. 4, 2007, pages 286 - 290, XP009091574, ISSN: 1557-9190 *
MALONEY DAVID G ET AL: "Fc(gamma) receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL pateints treated with chop followed by rituximab (SWOG 9800).", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 170A, XP002457178, ISSN: 0006-4971 *
WENG W-K ET AL: "Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients with Follicular Lymphoma", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 21, no. 21, 1 November 2003 (2003-11-01), pages 3940 - 3947, XP003013385, ISSN: 0732-183X *

Also Published As

Publication number Publication date
CA2650730A1 (en) 2007-11-08
EP3026123A1 (en) 2016-06-01
US20100291549A1 (en) 2010-11-18
AU2007244683A1 (en) 2007-11-08
US8592149B2 (en) 2013-11-26
EP2027291A2 (en) 2009-02-25
US20140170670A1 (en) 2014-06-19
WO2007127936A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007127936A3 (en) Methods and compositions for antibody therapy
WO2009062081A3 (en) Methods and compositions for antibody or vaccine therapy
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
EP2500362A3 (en) Humanized antibodies against TL1A
BR0315161A (en) Isolated antibody, isolated polynicleotide, vector, host cell, method of producing an antibody, and, composition
EP1912674A4 (en) BISPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHODS OF USE THEREOF
UA90082C2 (en) Isolated monoclonal antibody which binds to and inhibits human cd25
MX2008009886A (en) Antibodies that bind par-2.
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
WO2007005874A3 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
ATE373719T1 (en) HUMANIZED ANTIBODIES AGAINST CCR2 AND METHOD OF USE THEREOF
WO2010009987A3 (en) Diagnostic antibody assay
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2009113814A3 (en) Protein marker for early diagnosis of liver cancer
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
WO2006084092A3 (en) Antibodies to oncostatin m receptor
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
WO2006036175A3 (en) Wnt proteins and detection and treatment of cancer
WO2006036179A3 (en) Frizzled proteins and detection and treatment of cancer
WO2008025964A3 (en) Antibodies to an epitope of agr2. assays and hybridomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761485

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2650730

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007244683

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6445/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007761485

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007244683

Country of ref document: AU

Date of ref document: 20070427

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12298661

Country of ref document: US